Advertisement

Cancer Immunology, Immunotherapy

, Volume 31, Issue 6, pp 373–380 | Cite as

Indomethacin modulation of Adriamycin-induced effects on multiple cytolytic effector functions

  • Darbie L. Maccubbin
  • Stefan A. Cohen
  • M. Jane Ehrke
Original articles

Summary

The anticancer agent, Adriamycin (ADM), in addition to being a potent cytotoxic drug has been shown to be an effective immunomodulator. This study was undertaken to determine whether ADM-induced changes in the production of prostaglandins (particularly PGE2) are involved in ADM-associated modifications of selected host defenses. Spleen cells from normal or ADM-treated (5 mg/kg; day −5) C57BL/6 mice were assessed for the following activities: fresh (day 0) and cultured natural killer (NK), cytotoxic T lymphocyte, lymphokine-activated killer (LAK), Fc-dependent phagocytosis and tumoricidal macrophage. All activities were assessed with and without the addition of indomethacin, an inhibitor of the first step of the cyclo-oxygenase pathway of prostaglandin synthesis. Depending on culture conditions, the cytotoxic T lymphocyte and splenic tumoricidal macrophage activities were either unaffected or were augmented by ADM treatment of the spleen donor mice or by addition of indomethacin to the culture, and these effects were apparently independent of one another. In contrast, ADM treatment generally resulted in reduced NK and LAK activities relative to control and elevated Fc-dependent phagocytosis. The addition of indomethacin to the culture effectively reversed these effects. Furthermore, spleen cells from ADM-treated mice were found to produce twice the amount of PGE2 in culture compared to cells from untreated mice. Finally, the direct addition of PGE2 to NK cultures resulted in a dose-dependent inhibition of NK activity and the dose required was comparable to the amount of PGE2 produced by cultured spleen cells from ADM-treated mice. Taken together, these results indicate that at least some of the immunomodulatory effects of ADM are an indirect result of ADM-induced changes in PGE2 production.

Keywords

Natural Killer Indomethacin PGE2 Adriamycin Spleen Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bachur NR, Gordon SI, Gee MV (1977) Anthracycline antibiotic augmentation of microsomal electron transport and free radical formation. Mol Pharmacol 13: 901Google Scholar
  2. 2.
    Brunda MJ, Herberman RB, Holden HT (1980) Inhibition of murine natural killer cell activity by prostaglandins. J Immunol 124: 2682Google Scholar
  3. 3.
    Chouaib S, Welte K, Mertelsmann R, DuPont B (1985) Prostaglandin E2 acts at two distinct pathways of T lymphocyte activation: inhibition of interleukin 2 production and down-regulation of transferrin receptor expression. J Immunol 135: 1172Google Scholar
  4. 4.
    Cohen SA, Ehrke MJ, Mihich E (1975) Mouse effector functions involved in the antibody-dependent cellular cytotoxicity to xenogeneic erythrocytes. J Immunol 115: 1007Google Scholar
  5. 5.
    Cohen SA, Ehrke MJ, Ryoyama K, Mihich E (1982) Augmentation of the phagocytic activity of murine spleen cell populations induced by Adriamycin. Immunopharmacology 5: 75Google Scholar
  6. 6.
    Cohen SA, Salazar D, Wicher J (1983) Adriamycin-induced activation of NK activity may initially involve LAF production. Cancer Immunol Immunother 15: 188Google Scholar
  7. 7.
    Djeu DY, Heinbaugh JA, Vieira WD, Holden HT, Herberman RB (1979) The effect of immunopharmacological agents on mouse natural cell-mediated cytotoxicity and on its augmentation by poly I: C. Immunopharmacology 1: 231Google Scholar
  8. 8.
    Droller MJ, Perlmann P, Schneider MU (1978) Enhancement of natural and antibody-dependent lymphocyte cytotoxicity by drugs which inhibit prostaglandin production by tumor target cells. Cell Immunol 39: 154Google Scholar
  9. 9.
    Droller MJ, Schneider MU, Perlmann P (1978) A possible role of prostaglandins in the inhibition of natural and antibody-dependent cell-mediated cytotoxicity against tumor cells. Cell Immunol 39: 165Google Scholar
  10. 10.
    Ehrke MJ, Ryoyama K, Tomazic V, Cohen SA, Mihich E (1980) Selective imbalances of cellular immune responses by Adriamycin. Recent Results Cancer Res 75: 195Google Scholar
  11. 11.
    Ehrke MJ, Cohen SA, Mihich E (1982) Selective effects of Adriamycin on murine host defense systems. Immunol Rev 65: 55Google Scholar
  12. 12.
    Ehrke MJ, Tomazic V, Ryoyama K, Cohen SA, Mihich E (1983) Adriamycin induced immunomodulation: dependence upon time of administration. Int J Immunopharmacol 5: 43Google Scholar
  13. 13.
    Ehrke MJ, Ryoyama K, Cohen SA (1984) Cellular basis for Adriamycin-induced augmentation of cell-mediated cytotoxicity in culture. Cancer Res 44: 2497Google Scholar
  14. 14.
    Ehrke MJ, Maccubbin D, Ryoyama K, Cohen SA, Mihich E (1986) Correlation between Adriamycin-induced augmentation of interleukin 2 production and of cell mediated cytotoxicity. Cancer Res 46: 54Google Scholar
  15. 15.
    Ehrke MJ, Mihich E, Berd D, Mastrangelo MJ (1989) Effects of anticancer drugs on the immune system in humans. Semin Oncol 16: 230Google Scholar
  16. 16.
    Flower RJ (1974) Drugs which inhibit prostaglandin biosynthesis. Pharmacol Rev 26: 33Google Scholar
  17. 17.
    Handa K, Sato S (1975) Generation of free radicals of quinone group containing anticancer chemicals in NADPH-microsome system as evidenced by initiation of sulfite oxidation. Gann 66: 43Google Scholar
  18. 18.
    Hember ME, Cook HW, Lands WEM (1979) Prostaglandin biosynthesis can be triggered by lipid peroxides. Arch Biochem Biophys 193: 340Google Scholar
  19. 19.
    Herberman RB (1987) Lymphokine-activated killer activity: characteristics of effector cells and their progenitors in blood and spleen. Immunol Today 8: 178Google Scholar
  20. 20.
    Hersey P (1973) Macrophage effector function. An in vitro system of assessment. Transplantation 15: 282Google Scholar
  21. 21.
    Hoffmann CC, Ehrke MJ, Mihich E (1979) Temporal specificity of procarbazine in the inhibition of mouse immune responses to allogeneic tumor. J Immunopharmacol 1: 157Google Scholar
  22. 22.
    Lala PK, Parhar RS, Singh P (1986) Indomethacin therapy abrogates the prostaglandin-mediated suppression of natural killer activity in tumor-bearing mice and prevents tumor metastasis. Cell Immunol 99: 108Google Scholar
  23. 23.
    Leung KH, Koren HS (1982) Regulation of human natural killing. II. Protective effect of interferon on NK cells from suppression by PGE2. J Immunol 129: 1742Google Scholar
  24. 24.
    Leung KH, Mihich E (1980) Prostaglandin modulation of development of cell-mediated immunity in culture. Nature 288: 597Google Scholar
  25. 25.
    Lown JW (1983) The mechanism of action of quinone antibiotics. Mol Cell Biochem 55: 17Google Scholar
  26. 26.
    Maca RD (1983) The effects of prostaglandins on the proliferation of cultured human T lymphocytes. Immunopharmacology 6: 267Google Scholar
  27. 27.
    Mace K, Mayhew E, Mihich E, Ehrke MJ (1988) Alterations in murine host defense functions by Adriamycin or liposome-encapsulated Adriamycin. Cancer Res 48: 130Google Scholar
  28. 28.
    Mantovani A, Luini W, Peri G, Vecchi A, Spreafico F (1978) Effects of chemotherapeutic agents on natural cell-mediated cytotoxicity in mice. J Natl Cancer Inst 61: 1255Google Scholar
  29. 29.
    Mantovani A, Candiani P, Luini W, Salmona M, Spreafico F, Garattini S (1979) Effects of chemotherapeutic agents on host defense mechanisms: its possible relevance for the antitumoral activity of these drugs. In: Current trends in tumor immunology; Ferrone S, Gorini S, Herberman RB, Reisfeld RA (eds). Garland Press, New York, p 139Google Scholar
  30. 30.
    Myers CE, McGuire WR, Liss RH, Ifrim I, Grotzinger K, Young RC (1977) Adriamycin: The role of lipid peroxidation in cardiac toxicity and tumor response. Science 197: 165Google Scholar
  31. 31.
    Nakata K, Kashimoto S, Yoshida H, Oku T, Nakamura S (1988) Augmented antitumor effect of recombinant human interleukin-1 α by indomethacin. Cancer Res 48: 584Google Scholar
  32. 32.
    Orsini R, Pavelic Z, Mihich E (1977) Increased primary cell mediated immunity in culture subsequent to Adriamycin or daunorubicin treatment of spleen donor mice. Cancer Res 37: 1719Google Scholar
  33. 33.
    Ortaldo JR, Mason A, Overton R (1986) Lymphokine-activated killer cells: analysis of progenitors and effectors. J Exp Med 164: 1193Google Scholar
  34. 34.
    Panje NR (1981) Regression of head and neck carcinoma with a prostaglandin synthesis inhibitor. Arch Otolaryngol 107: 658Google Scholar
  35. 35.
    Razin E, Bablminger S, Globerson A (1978) Effect of prostaglandins on phagocytosis of sheep erythrocytes by mouse peritoneal macrophages. J Reticuloendothel Soc 23: 237Google Scholar
  36. 36.
    Salazar D, Cohen SA (1984) Multiple tumoricidal effector mechanisms induced by Adriamycin. Cancer Res 44: 2561Google Scholar
  37. 37.
    Santoni A, Riccardi C, Sorci V, Herberman R (1980) Effects of Adriamycin on the activity of mouse natural killer cells. J Immunol 124: 2329Google Scholar
  38. 38.
    Schwartz HS (1983) Mechanisms of selective cytotoxicity of Adriamycin, daunorubicin and related anthracyclines. In: Molecular aspects of anticancer drug action: topics in molecular and structural biology, vol 3. Neidle S, Waring MJ (eds) MacMillan, New YorkGoogle Scholar
  39. 39.
    Tomazic V, Ehrke MJ, Mihich E (1981) Augmentation of the development of immune responses of mice against allogeneic tumor cells after Adriamycin treatment. Cancer Res 41: 3370Google Scholar
  40. 40.
    Tzung S-P, Gaines KC, Ehrke MJ, Cohen SA (1990) Suppression of lymphokine-activated killer cell induction from murine liver Kupffer cells and hepatocytes. Hepatology (in press)Google Scholar
  41. 41.
    Venuto RC, O'Dorisio T, Stein JH, Ferris TF (1975) Uterine prostaglandin E secretion and uterine blood flow in the pregnant rabbit. J Clin Invest 55: 193Google Scholar
  42. 42.
    Walker C, Kristensen F, Bettens F, deWeck AL (1983) Lymphokine regulation of activated (G1) lymphocytes. I. Prostaglandin E2-induced inhibition of interleukin 2 production. J Immunol 130: 1770Google Scholar
  43. 43.
    Webb DR, Nowowiejeski I (1977) The role of prostaglandins in the control of the primary 19 s immune response to SRBC. Cell Immunol 33: 1Google Scholar
  44. 44.
    Young RC, Ozols RF, Myers CE (1981) The anthracycline antineoplastic drugs. N Engl J Med 305: 139Google Scholar
  45. 45.
    Zusman RM, Spector D, Caldwell BN, Speroff L, Schneider G, Mulrow PJ (1971) The effect of chronic sodium loading and sodium restriction on plasma prostaglandins A, E and F concentrations in normal humans. J Clin Invest 52: 1093Google Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • Darbie L. Maccubbin
    • 1
  • Stefan A. Cohen
    • 2
  • M. Jane Ehrke
    • 1
  1. 1.Grace Cancer Drug CenterRoswell Park Memorial InstituteBuffaloUSA
  2. 2.V. A. Medical CenterDepartment of Medicine, State University of New York at BuffaloBuffaloUSA

Personalised recommendations